Vir Biotechnology, Inc. (VIR) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VIR Revenue Growth
Revenue Breakdown (FY 2025)
VIR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
VIR Revenue Analysis (2017–2025)
As of May 8, 2026, Vir Biotechnology, Inc. (VIR) generated trailing twelve-month (TTM) revenue of $65.5 million, reflecting significant decline in growth of -101.0% year-over-year. The most recent quarter (Q1 2026) recorded $-29,000 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, VIR's 5-year compound annual growth rate (CAGR) stands at +0.4%, indicating moderate growth over time. The company achieved its highest annual revenue of $1.62 billion in 2022.
Revenue diversification analysis shows VIR's business is primarily driven by License And Collaboration Revenue (92%), Other Revenue (5%), and Grant (3%). With over half of revenue concentrated in License And Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+5.9% YoY), MNKD (+21.2% YoY), and AGEN (+10.4% YoY), VIR has underperformed the peer group in terms of revenue growth. Compare VIR vs REGN →
VIR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VIRCurrent | $65M | -101.0% | +0.4% | -682.7% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 MNKD | $349M | +21.2% | +39.9% | 11.1% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% | |
 SIGA | $95M | -22.1% | -5.4% | 25.1% |
VIR Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $68.6M | -7.6% | $56.9M | 82.9% | $-468,020,000 | -682.7% |
| 2024 | $74.2M | -13.9% | $-404,440,000 | -545.0% | $-587,165,000 | -791.3% |
| 2023 | $86.2M | -94.7% | $-486,647,000 | -564.7% | $-684,305,000 | -794.0% |
| 2022 | $1.62B | +47.5% | $994.8M | 61.6% | $833.1M | 51.6% |
| 2021 | $1.10B | +1529.0% | $581.5M | 53.1% | $420.8M | 38.4% |
| 2020 | $67.2M | +9357.8% | $67.2M | 100.0% | $-296,980,000 | -441.6% |
| 2019 | $711K | -18.1% | $711K | 100.0% | $-177,979,000 | -25032.2% |
| 2018 | $868K | +482.6% | $-99,361,000 | -11447.1% | $-118,692,000 | -13674.2% |
| 2017 | $149K | - | $-62,363,000 | -41854.4% | $-81,497,000 | -54696.0% |
See VIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VIR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VIR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVIR — Frequently Asked Questions
Quick answers to the most common questions about buying VIR stock.
Is VIR's revenue growth accelerating or slowing?
VIR revenue declined -101.0% year-over-year, contrasting with the 5-year CAGR of +0.4%. TTM revenue fell to $65M. This reverses the prior growth trend.
What is VIR's long-term revenue growth rate?
Vir Biotechnology, Inc.'s 5-year revenue CAGR of +0.4% reflects the variable expansion pattern. Current YoY growth of -101.0% is below this long-term average.
How is VIR's revenue distributed by segment?
VIR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.